Photo de la dixième édition du festival Amani

Le festival Amani pourrait intégrer les entrepreneurs déplacés dans ses programmes de promotion des entrepreneurs locaux.Cette intention a été révélée par Guillaume Bisimwa, directeur du Festival Amani, lors d’un point de presse tenu ce lundi 18 novembre 2024, revenant sur le bilan de la dixième édition du Festival.

Depuis plus de dix ans, le festival Amani encadre, dans le cadre de la promotion de l’économie locale, des projets d’entreprise qui passent par un concours entrepreneurial à chaque édition. 

Mr Guillaume Bisimwa, directeur du Festival Amani 

Cette année, le Festival Amani a célébré son dixième anniversaire dans un contexte particulier où la ville de Goma est asphyxiée par la montée du déplacement massif des populations causant ainsi, l’augmentation spontanée des sites aux environs de la Capitale provinciale du Nord-Kivu, une conséquence directe de la guerre du M23 et ses alliés.

Toutefois, le bilan de ce festival demeure épatant : plus de 32 micro-entreprises et plus de 500 emplois stables ont été créés grâce à ces programmes du festival Amani, selon son directeur.

Les entrepreneurs déplacés pourraient également intégrer ces programmes d’accompagnement d’entreprises, en croire Guillaume Bisimwa, directeur du Festival Amani.

Et d’ajouter :

Les entrepreneurs déplacés, pourquoi pas… C’est une bonne question de réflexion. Comme on a des entrepreneurs qu’on promeut toujours ; on ne promet rien, mais on prend bonne note de la question.

Cette réponse n’affirme ni, ne rejette la possibilité de la mise en place d’un plan en faveur des entrepreneurs déplacés, mais revêt clairement une intention des organisateurs du Festival Amani de penser aux déplacés parmi lesquels, plusieurs ont fui avec des idées d’entreprises qui méritent orientation et accompagnement autant que celles d’autres entrepreneurs ayant déjà bénéficié de ces programmes. 

On ne peut qu’attendre les fruits de la réflexion de l’équipe du festival sur cette question. 

L’intégration d’un programme spécial dédié à l’accompagnement des entrepreneurs déplacés pourrait renforcer le caractère philanthropique et rassembleur de la vision du festival Amani. 

Notons que pour cette dixième édition, des séances où des panels sur l’entrepreneuriat étaient attendus n’ont pas eu lieu suite aux contraintes organisationnelles. 

Prévu pour trois jours, soit du vendredi 15 au dimanche 17 novembre, Goma a fêté la dixième édition du festival Amani du samedi 16 au dimanche 17 novembre 2024, soit un jour de moins de spectacles.

Meschac Tsongo

8 thoughts on “Nouveauté entrepreneuriale dans le festival Amani: les entrepreneurs déplacés mis au premier plan”
  1. What You Should Know About Ipamorelin’s Side Effects

    Common Adverse Reactions Associated with Ipamorelin

    Exploring the Safety Profile of Ipamorelin

    How Ipamorelin May Affect Your Health: A Look at Its Side Effects

    Ipamorelin is a synthetic growth hormone releasing peptide (GHRP) that has gained attention for its potential benefits in muscle
    growth, fat loss and anti‑aging therapy. While it is generally considered to have a favorable safety profile compared to other GHRPs, users—particularly women—should
    be aware of possible side effects that can arise during use or after discontinuation. Understanding these risks allows individuals to make informed decisions
    about whether ipamorelin is suitable for their health goals.

    cjc 1295 / ipamorelin side effects Side Effects

    The most commonly reported side effects among female users are mild and often transient, but they
    can still affect daily life and comfort. These include:

    Water Retention and Bloating

    Some women experience a subtle swelling in the extremities or abdomen due to increased retention of fluids.
    This is typically temporary and resolves once the peptide is
    discontinued.

    Headaches and Migraines

    Head pain can range from tension‑type headaches to more severe migraines.

    Women who have a history of migraine disorders may notice an uptick in frequency or intensity
    during ipamorelin therapy.

    Insomnia or Sleep Disturbances

    Growth hormone activity influences circadian rhythms.

    A minority of users report difficulty falling asleep, fragmented sleep,
    or altered dream patterns while on the peptide.

    Digestive Issues

    Nausea, bloating and occasional abdominal discomfort have been noted, especially when starting a
    new dosing regimen or increasing frequency.

    Mood Changes

    Some women describe mood swings, irritability,
    or feelings of anxiety. The mechanism may involve changes in neuroendocrine pathways influenced by growth hormone release.

    Skin Reactions at Injection Site

    Since ipamorelin is typically administered subcutaneously,
    users can experience redness, itching or mild swelling where the needle
    penetrates. Proper injection technique and rotating sites help reduce irritation.

    Increased Appetite

    Growth hormone stimulates metabolism and can sometimes trigger a heightened
    sense of hunger, leading to increased caloric intake if not monitored.

    Hormonal Imbalances

    Although rare, prolonged use may interfere with the hypothalamic‑pituitary axis, potentially affecting estrogen or progesterone levels in women. This could manifest as menstrual irregularities or
    changes in libido.

    Light‑headedness and Weakness

    A subset of users report feeling faint or experiencing a
    sudden drop in blood pressure after injection, which can lead to dizziness or light‑headedness.
    This is often associated with rapid fluid shifts or minor drops in systemic vascular resistance.

    Rare Allergic Reactions

    In exceptional cases, women may develop an allergic reaction that includes
    rash, swelling of the face or difficulty breathing.
    Immediate medical attention is required if such symptoms occur.

    When considering ipamorelin, it is essential to monitor for these
    side effects and report any persistent or severe symptoms to a healthcare professional.

    What Is Ipamorelin?

    Ipamorelin is a pentapeptide that acts as a selective growth hormone
    secretagogue. It binds to the ghrelin receptor in the pituitary gland, stimulating the release of growth hormone without significantly affecting cortisol
    or prolactin levels. The peptide’s short half‑life and high selectivity for the growth hormone axis
    make it attractive for therapeutic uses such as:

    Enhancing muscle repair and strength in athletes

    Promoting fat loss while preserving lean body mass

    Supporting joint health and bone density

    Potential anti‑aging effects by boosting endogenous growth
    hormone production

    Unlike older GHRPs, ipamorelin has a lower propensity to cause adverse metabolic changes or significant appetite
    stimulation. However, because it still influences the endocrine system, users—especially women with preexisting hormonal conditions—should approach
    its use cautiously.

    Feeling Light‑headed or Weak

    Light‑headedness and weakness are among the most noticeable side effects
    for some women taking ipamorelin. The underlying mechanisms include:

    Vascular Changes

    Ipamorelin can cause subtle vasodilation, leading to a temporary drop in blood pressure.
    When standing quickly after an injection, this may produce dizziness or
    faintness.

    Fluid Redistribution

    Growth hormone promotes fluid retention and changes in plasma volume.
    Rapid shifts between the vascular compartment and interstitial spaces can alter cerebral perfusion, resulting in light‑headed sensations.

    Neuromuscular Effects

    The peptide’s influence on muscle metabolism might temporarily affect neuromuscular coordination, especially during the initial days of therapy or after dose adjustments.

    Anxiety or Stress Response

    The feeling of dizziness can be amplified by anxiety, particularly if the
    user is uncertain about the safety profile of the drug.

    To manage these symptoms, women should:

    Stand slowly from seated or lying positions.

    Maintain adequate hydration before and during dosing.

    Use lower starting doses and gradually titrate up under professional
    guidance.

    Monitor blood pressure if possible; a sudden drop warrants medical evaluation.

    Consider timing injections at night to minimize daytime dizziness.

    If light‑headedness persists beyond the first few
    days of therapy or is accompanied by fainting, chest pain, shortness of breath or severe
    weakness, discontinuation and consultation with a healthcare provider are
    advised. In most cases, symptoms abate as the body adapts
    to the peptide’s hormonal influence.

Laisser un commentaire

Votre adresse e-mail ne sera pas publiée. Les champs obligatoires sont indiqués avec *